XML 27 R17.htm IDEA: XBRL DOCUMENT v3.25.3
Subsequent Event
9 Months Ended
Sep. 30, 2025
Subsequent Events [Abstract]  
SUBSEQUENT EVENT SUBSEQUENT EVENT
On October 17, 2025, Cumberland signed several agreements with RedHill BioPharma, Ltd. to jointly commercialize Talicia®. The FDA-approved oral capsule is indicated for the treatment of Helicobacter pylori infection in adults, a bacterial infection and leading risk factor for gastric cancer. Under the terms of the agreements, Cumberland and RedHill formed a new, jointly owned company. RedHill contributed all its Talicia related assets to the new company, including the product’s international licenses with associated revenues for a 70% ownership position. Cumberland will provide a $4 million in investment capital over a two-year period and receiving the 30% remaining shares. Through a co-commercialization agreement, Cumberland will assume responsibility for the product's distribution and sale of Talicia in the US. Cumberland will record the product sales and equally share Talicia's net revenue. Cumberland will also provide an annual investment of up to $2 million to cover certain distribution, marketing and sales costs. The Company is currently evaluating the accounting impact of the addition.